The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost ...

Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA ...

Bagsværd, Denmark, 13 November 2025 - Today, it was announced that Mikael Dolsten will not seek election to the Board of ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

() -Telehealth company Mangoceuticals said on ​Thursday it has partnered ‌with Eli Lilly and Novo Nordisk ‌to sell the ...

Carol Saffran started taking Ozempic a year ago to regulate her blood sugar after other medications were ineffective. She was ...